New attenuated anthrax vaccine
新型减毒炭疽疫苗
基本信息
- 批准号:7056575
- 负责人:
- 金额:$ 38.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-01 至 2008-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Anthrax is a rare, but deadly disease and poses a serious threat as a bioterror agent. The current anthrax vaccine uses needle injection and requires repeated immunizations for inducing protection and frequent boosts for maintaining immunity, thus making it impractical for mass immunization against this rare disease. To protect against bioterror threats, an ideal anthrax vaccine would have the following desired features: 1) inducing immediate protection so that it can be used as an emergent prophylaxis, and 2) inducing long-lasting immunity by a single, simple immunization procedure suitable for mass immunization. We have tested a novel vaccine platform and our preliminary results indicate that this immunization strategy induce 1) a rapid innate response in the lung that may confer immediate protection against inhalational anthrax, and 2) stable memory B and T cells that will likely provide long-lasting immunity. The objective of this application is to develop new attenuated strains suitable and safe for further development and clinical testing of our novel vaccine platform. The specific aims of this Phase I STTR application are: 1) to construct new attenuated strains and test their virulence and potential as highly attenuated vaccine strains; 2) to test the ability of our new vaccine strains to induce the rapid innate response in the lung and to generate high levels of antibodies and long-lasting T cell memory. At the end of this Phase I study, we hope to identify new attenuated vaccine strains that are severely attenuated yet highly immunogenic. This will set the stage for the Phase II study in which we will test these new attenuated strains for inducing protective immunity against fully virulent B. anthracis in small animal models and non-human primates. With the combination of new attenuated strains and a novel vaccine platform, our ultimate goal is to develop a vaccination strategy suitable for mass immunization to induce immediate and long-term protective immunity against pulmonary anthrax.
描述(由申请人提供):炭疽是一种罕见但致命的疾病,作为生物恐怖剂构成严重威胁。目前的炭疽疫苗使用针头注射,需要反复免疫以诱导保护和频繁加强以维持免疫力,因此对于这种罕见疾病的大规模免疫是不切实际的。为了保护免受生物恐怖威胁,理想的炭疽疫苗应具有以下所需的特征:1)诱导立即保护,使其可用作紧急预防,以及2)通过适合于大规模免疫的单一简单免疫程序诱导持久免疫。我们已经测试了一种新的疫苗平台,我们的初步结果表明,这种免疫策略诱导1)肺中的快速先天反应,可以立即提供针对吸入性炭疽的保护,以及2)稳定的记忆B和T细胞,可能提供持久的免疫力。本申请的目的是开发新的减毒菌株,适用于我们新型疫苗平台的进一步开发和临床试验。本次I期STTR申请的具体目的是:1)构建新的减毒株,并测试其毒力和作为高度减毒疫苗株的潜力; 2)测试我们的新疫苗株诱导肺部快速先天性应答的能力,以及产生高水平抗体和持久T细胞记忆的能力。在这项I期研究结束时,我们希望鉴定出新的减毒疫苗株,这些疫苗株是严重减毒的,但具有高度免疫原性。这将为II期研究奠定基础,在该研究中,我们将测试这些新的减毒株诱导针对完全强毒B的保护性免疫。在小动物模型和非人类灵长类动物中的炭疽病。结合新的减毒株和新的疫苗平台,我们的最终目标是开发适合大规模免疫的疫苗接种策略,以诱导针对肺炭疽的即时和长期保护性免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hao Shen其他文献
Hao Shen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hao Shen', 18)}}的其他基金
Regenerative therapy for lung infection by S. pneumoniae
肺炎链球菌肺部感染的再生治疗
- 批准号:
9388099 - 财政年份:2017
- 资助金额:
$ 38.63万 - 项目类别:
Treating chronic viral infection by epigenetic reprogramming of exhausted CD8 T cells
通过对耗尽的 CD8 T 细胞进行表观遗传重编程来治疗慢性病毒感染
- 批准号:
9768950 - 财政年份:2017
- 资助金额:
$ 38.63万 - 项目类别:
The Impact of Bacterial Co-Infectin on Respiratory Virus-Specific T cell Response
细菌共感染对呼吸道病毒特异性 T 细胞反应的影响
- 批准号:
8089283 - 财政年份:2010
- 资助金额:
$ 38.63万 - 项目类别:
Molecular basis of defective CD8 T cells during chronic viral infection
慢性病毒感染期间缺陷型 CD8 T 细胞的分子基础
- 批准号:
7522985 - 财政年份:2009
- 资助金额:
$ 38.63万 - 项目类别:
The Impact of Bacterial Co-Infectin on Respiratory Virus-Specific T cell Response
细菌共感染对呼吸道病毒特异性 T 细胞反应的影响
- 批准号:
7746167 - 财政年份:2009
- 资助金额:
$ 38.63万 - 项目类别:
Molecular basis of defective CD8 T cells during chronic viral infection
慢性病毒感染期间缺陷型 CD8 T 细胞的分子基础
- 批准号:
7835681 - 财政年份:2009
- 资助金额:
$ 38.63万 - 项目类别:
Modulation of T cell Responses by Ebola Glycoprotein
埃博拉糖蛋白对 T 细胞反应的调节
- 批准号:
6570789 - 财政年份:2002
- 资助金额:
$ 38.63万 - 项目类别:
Modulation of T cell Responses by Ebola Glycoprotein
埃博拉糖蛋白对 T 细胞反应的调节
- 批准号:
6656939 - 财政年份:2002
- 资助金额:
$ 38.63万 - 项目类别:
相似国自然基金
CD8+T细胞亚群在抗MDA5抗体阳性皮肌炎中的致病机制研究
- 批准号:82371805
- 批准年份:2023
- 资助金额:45.00 万元
- 项目类别:面上项目
沙眼衣原体pORF5蛋白功能及其与宿主细胞相互作用的研究
- 批准号:30970165
- 批准年份:2009
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Molecular basis of glycan recognition by T and B cells
T 和 B 细胞识别聚糖的分子基础
- 批准号:
10549648 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection
原发性母体感染后预防先天性巨细胞病毒传播的免疫相关性的识别和建模
- 批准号:
10677439 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Mucosal immunity to sapovirus in early childhood
幼儿期对沙波病毒的粘膜免疫
- 批准号:
10677051 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Characterizing antibody responses to HIV-1 vaccination in next-generation immune humanized mice
表征下一代免疫人源化小鼠对 HIV-1 疫苗接种的抗体反应
- 批准号:
10673292 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons
研究 RNA 复制子诱导的 SIV/HIV T 和 B 细胞免疫的保护功效
- 批准号:
10673223 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT study
感染和未感染艾滋病毒的幼儿结核感染的进展:PROTECT 研究
- 批准号:
10641389 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别: